Bioventus Inc.

NASDAQ:BVS

Medical - Devices

Healthcare
$10.62 +2.11%

+$0.18 today

Market cap
$727.20M
Beta
0.67
P/E (TTM)
20.6
EPS (TTM)
$0.42
52W Low $5.81High $11.25

Volume 0.70M

Average 0.56M

BVS Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Bioventus Inc.NASDAQ: BVS

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue growth accelerates

Q1 FY2026 revenue of $132.09M rose 6.6% year over year, ahead of the +1.5% change in trailing-twelve-month revenue. Sequentially, it fell 16.3% from the prior quarter. Over 3 fiscal years it compounded at +3.5% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 4 analysts of $592.31M (+4.3%) for the fiscal year ending Dec 2026, a step up from the -0.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$132.09M-16.3% QoQ
Last fiscal yearDec 2025
$568.09M-0.9% YoY
LTMMar 2026
$576.3M+1.5% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.6%+5.3%-1.4 pp
1 year-0.9%+4.3%+5.2 pp
3-year CAGR+3.5%+6.0%+2.4 pp
5-year CAGR+4.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
568.09M USD
Year-over-year change
-0.9%
4-year CAGR
+7.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How BVS compares with its peers on the latest reported figures

  • BVS's LTM Mar 2026 revenue of $576.3M is the 4th highest of the 9 companies compared; the peer median is $451.49M.
  • Its year-over-year change of +1.5% is the 7th highest of 9, against a peer median of +6.1%.
  • Over three fiscal years its annual growth of +3.5% compares with a peer median of +11.9%.
BVS Competitors Peer median
Revenue for BVS and competitors
Company Period LTM YoY 3-year CAGR
SNNSmith & Nephew plcFY2025$6.16B +6.1%+5.7%
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026$1.64B +1.2%+1.6%
OFIXOrthofix Medical Inc.LTM Mar 2026$825.37M +2.6%+21.3%
BVSBioventus Inc.LTM Mar 2026$576.3M +1.5%+3.5%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$513.57M +11.9%+7.7%
MDXGMiMedx Group, Inc.LTM Mar 2026$389.42M +10.5%+16.1%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$121.91M -0.3%+32.2%
ANIKAnika Therapeutics, Inc.LTM Mar 2026$116.26M +23.2%-0.3%
TELATELA Bio, Inc.LTM Jun 2026$79.91M +6.1%+24.7%
Peer median (excluding BVS) $451.49M+6.1%+11.9%

Competitors are the stored peer set for BVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue430.9M512.12M512.35M573.28M568.09M
Cost of Revenue128.19M181.04M184.15M185.05M185.66M
Gross Profit302.71M331.08M328.19M388.23M382.43M
Gross Margin70.3%64.6%64.1%67.7%67.3%
Research & Development19.04M23.85M13.45M13.64M12.11M
Selling, General & Admin254.25M332.13M303.88M327.09M311.77M
Operating Expenses290.65M498.31M409.92M400.21M323.88M
Depreciation & Amortization34.88M55.4M57.37M49.56M47.01M
EBITDA45.48M(121.61M)(23.07M)39.22M99.21M
EBITDA Margin10.6%-23.7%-4.5%6.8%17.5%
Operating Income12.06M(167.23M)(81.73M)(11.98M)58.55M
Operating Margin2.8%-32.7%-16.0%-2.1%10.3%
Interest Income00000
Interest Expense1.11M12.02M40.68M38.79M26.49M
Other Income / Expenses(2.57M)(21.79M)(39.39M)(37.15M)(32.84M)
Income Before Tax9.49M(189.03M)(121.11M)(49.13M)25.71M
Pre-Tax Margin2.2%-36.9%-23.6%-8.6%4.5%
Income Tax Expense(1.97M)(44.37M)85K(5.29M)(1.57M)
Net Income19.38M(158.7M)(156.23M)(33.54M)22.73M
Net Margin4.5%-31.0%-30.5%-5.9%4.0%
EPS (Basic)(0.15)(2.59)(2.49)(0.52)0.34
EPS (Diluted)(0.15)(2.59)(2.49)(0.52)0.33
Weighted Avg Shares45.47M61.39M62.65M65.36M66.62M
Weighted Avg Shares (Diluted)45.47M61.39M62.65M65.36M68.91M

Bioventus Inc.

NASDAQ:BVS

Intrinsic Alpha fair value

Locked

Current Price

$10.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.